Table 1.
Randomized study groups, doses and routes of HIV-DNA and HIV-MVA vaccinations.
Fig 1.
Number of individuals screened, randomized and allocated to the three vaccination groups and withdrawn from the trial.
Table 2.
Baseline characteristics.
Fig 2.
Proportion and number of participants with (A) local and (B) systemic solicited adverse events post HIV-DNA and HIV-MVA by randomization arm.
Table 3.
Numbers and percent of non-solicited clinical adverse events by grade and relationship to vaccination.
Table 4.
Proportion of ELISpot responders to Gag and/or Env peptides two weeks post first and second HIV-MVA vaccination in each of the HIV-DNA primed groups.
Fig 3.
Magnitude of IFN-γ ELISpot responses.
The magnitude of IFN-γ ELISpot responses to (A) Gag and (B) Env two weeks after the first HIV-MVA vaccination and to (C) Gag and (D) Env two weeks after the second HIV-MVA vaccination. Data is shown for each of the HIV-DNA primed groups. ELISpot responses were considered positive if the number of SFC was >55 spots/million PBMCs and 4 times the background value. The dashed line is at a cut-off of 55 SFC/million PBMCs. Responders are shown by filled circles and non-responders are shown by open circles.
Table 5.
Magnitude of ELISpot responses measured as SFC/106 PBMCs 2 weeks after the first and second HIV-MVA vaccination in each of the HIV-DNA primed groups.
Fig 4.
Magnitude of HIV-specific IFN-γ/IL-2 T cell responses.
The magnitude of HIV-specific IFN-γ/IL-2 T cell responses in responders as assessed by 4-colour ICS two weeks after the first (upper panel) and second (lower panel) HIV-MVA vaccination presented as Gag reactivity of CD4+ T cells (panels A and E) and of CD8+ T cells (panels B and F), and Env reactivity of CD4+ T cells (panels C and G) and of CD8+ T cells (panels D and H). The Gag-reactivity represents reactivity to either the MVA-CMDR-specific peptide pools or the HIV-DNA-specific peptide pool. A Gag HIV-DNA-specific peptide pool response is only given when the Gag MVA-CMDR-specific peptide pool response is negative. Gag-HIV-DNA-specific responses are given by triangles, while Gag and Env-HIV-CMDR-specific responses are given by circles.
Table 6.
The proportion of ICS responders to Gag or Env peptide pools two weeks after the first and second HIV-MVA vaccination in each of the HIV-DNA primed groups.
Fig 5.
Antibody endpoint titers to native HIV-1IIIB subtype B gp160 one month after the second HIV-MVA vaccination. Data is shown for each of the HIV-DNA priming groups. The dashed line shows a titer of 100, corresponding to a 1:100 serum dilution, the lowest dilution used in the assay.